Abstract
The widely spread MBT Drug Resistance to the first-line antitubercolosis drugs calls for the thorough study of DR to the second-line (SL) medications.
AIMS: to study the dynamics of MBT DR to the SL meds among TB patients.
METHODS: MBT DR was analyzed among 2182 patients with lung tuberculosis by sputum inoculation on Lowenstein-Jensen medium in Saratov region (RF) hospital in 2008-2015.
RESULTS: General DR to the SL drugs dropped by 24.8% to 67.2% (p<0.001). But the primary DR reached 63.0% (2009-38.2%). The secondary DR decreased to 59.7%; among chronics it reached 94.4%. PAS DR fell by 22.9% to 31.2% (p<0.001). Primary DR increased to 29.6%. Secondary DR showed a double reduction to 26.1% (p<0.001) and among chronic patients declined by 25.7% to 47.2% (p<0.001). DR to Ofloxacin lessened by 10.8% to 47.1% (p<0.05), but primary DR increased to 37.0%. Secondary diminished by 10.4% to 40.3%, among chronics by 9.7% to 75.0%. DR to Capreomycin dropped twice, to 26.5% (p<0.001). Primary DR fell to 14.8 %. Secondary diminished two times to 23.5% (p<0.001), the same rate among chronics-41.7% (p<0.001). DR to Kanamycin reduced by 21.1% to 32.3% (p<0.001), primary DR constituted 18.5%, secondary decreased by 19.5% to 28.6% (p<0.01) and almost twofold among chronics to 41.7% (p<0.001). DR to Amicacin dropped thrice to 20.1% (p<0.001). Primary DR diminished to 14.8%, secondary decreased four times to 16.0% (p<0.001), with chronics it reduced to 38.9% (p<0.001).
CONCLUSIONS: Positive tendencies in regard to SL drugs to MBT DR have been revealed. Primary and secondary DR decrease is recorded to Capreomycin, Kanamycin and Amicacin, and secondary DR is observed to Ofloxacin and PAS.
- Copyright ©the authors 2016